Technical Analysis for RVX - Resverlogix Corp.

Grade Last Price % Change Price Change
C 0.070 7.69% 0.005
RVX closed up 7.69 percent on Tuesday, November 12, 2024, on 5 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Stochastic Reached Overbought Strength 0.00%
Gapped Up Strength 0.00%
Overbought Stochastic Strength 0.00%
Fell Below 50 DMA Bearish 7.69%
Narrow Range Bar Range Contraction 7.69%
Gapped Down Weakness 7.69%
Crossed Above 50 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%

   Recent Intraday Alerts

Alert Time
Gapped Down (Full) 1 day ago
Down 1 ATR 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 5% 1 day ago
Down 3% 1 day ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Resverlogix Corp. Description

Resverlogix Corp. is a clinical-stage biotechnology company. The Company is a development-stage company, which is engaged in developing apabetalone (RVX-208), a first-in-class small molecule selective Bromodomain and ExtraTerminal domain (BET) inhibitor. Apabetalone is used for the treatment of patients with high-risk cardiovascular disease, (including peripheral arterial disease), diabetes mellitus, chronic kidney disease, Alzheimer's disease and orphan diseases. Apabetalone is being investigated in a Phase III clinical trial for the secondary prevention of major adverse cardiovascular events (MACE) in high risk patients with diabetes mellitus and chronic kidney disease. The Company initiated a Phase III clinical trial BETonMACE with apabetalone in high-risk cardiovascular disease patients with low high-density lipoprotein. It focuses on conducting a proof-of-concept clinical trial in patients with Paroxysmal Nocturnal Hemoglobinuria. The Company has not generated any revenues.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Clinic Beta Biotechnology Disease RTT Medical Specialties Diseases IPO Clinical Trial Diabetes Alzheimer's Disease Chronic Condition Chronic Kidney Diabetes Mellitus Kidney Disease

Is RVX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.095
52 Week Low 0.04
Average Volume 92,450
200-Day Moving Average 0.061
50-Day Moving Average 0.065
20-Day Moving Average 0.065
10-Day Moving Average 0.065
Average True Range 0.005
RSI (14) 53.49
ADX 12.27
+DI 34.199
-DI 32.214
Chandelier Exit (Long, 3 ATRs) 0.056
Chandelier Exit (Short, 3 ATRs) 0.069
Upper Bollinger Bands 0.072
Lower Bollinger Band 0.057
Percent B (%b) 0.86
BandWidth 23.876
MACD Line 0.001
MACD Signal Line 0.000
MACD Histogram 0.0006
Fundamentals Value
Market Cap 15.25 Million
Num Shares 218 Million
EPS 0.51
Price-to-Earnings (P/E) Ratio 0.14
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.070
Resistance 3 (R3) 0.070 0.070 0.070
Resistance 2 (R2) 0.070 0.070 0.070 0.070
Resistance 1 (R1) 0.070 0.070 0.070 0.070 0.070
Pivot Point 0.070 0.070 0.070 0.070 0.070
Support 1 (S1) 0.070 0.070 0.070 0.070 0.070
Support 2 (S2) 0.070 0.070 0.070 0.070
Support 3 (S3) 0.070 0.070 0.070
Support 4 (S4) 0.070